Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Sirolimus in Progressive or Symptomatic Epithelioid Hemangioendothelioma
NCT07684287Phase 2Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
A Phase 2 trial of nab-sirolimus in epithelioid hemangioendothelioma (EHE), sponsored by CSPC ZhongQi Pharmaceutical Technology. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
nab-sirolimus
03
Conditions
epithelioid hemangioendothelioma (EHE)
Beyond the preview
Go deeper on NCT07684287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07684287.